|
Post by myocat on Aug 7, 2019 15:23:21 GMT -5
Since when MNKD signs the agreement?
"Entered into exclusive marketing and distribution agreement with AMSL for Australia"
|
|
|
Post by Omega on Aug 7, 2019 15:28:37 GMT -5
Back on May 16, 2019 investors.mannkindcorp.com/news-releases/news-release-details/mannkind-announces-afrezzar-distribution-agreement-australiaMannKind Announces Afrezza® Distribution Agreement in AustraliaWESTLAKE VILLAGE, Calif., May 16, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) today announced that it has entered into an exclusive marketing and distribution agreement with the AMSL Diabetes division of Australasian Medical & Scientific Ltd. for the commercialization of Afrezza® (insulin human) Inhalation Powder in Australia.
"We are excited to partner with AMSL Diabetes to accelerate patients’ access to Afrezza in Australia," said Michael Castagna, Chief Executive Officer of MannKind Corporation. “This agreement with AMSL, our third international partnership for Afrezza, aligns us with a partner with a strong presence and knowledge of the diabetes market in Australia, giving us an opportunity to provide more healthcare providers and patients with a new option in their fight against diabetes." “Adding Afrezza to our portfolio is a significant step towards addressing the needs of Australian patients with diabetes who are looking for a mealtime insulin with a unique time-action profile,” said Richard Plowright, Managing Director of AMSL. “Through our exclusive partnership with MannKind, we can bring the benefits of inhalable insulin to patients across Australia.” Under the terms of the agreement, AMSL Diabetes will be responsible for obtaining regulatory and reimbursement approvals to distribute Afrezza in Australia. AMSL Diabetes will also be responsible for sales, marketing, and customer support and distribution activities. MannKind will retain responsibility for supply and manufacturing of Afrezza.
|
|